Nanomedicine News

RSS

New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.

23 Sep 2014

NANOBIOTIX Opens First US Office in Boston, Massachusetts

NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

From Nanobiotix 23 Sep 2014

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetic nanoparticles don’t have to be "one size fits all." Instead, individual magnetic nanoparticles can be tailored in an array of differing sizes and compositions to allow for heating them separately by varying the frequency and amplitude of an external alternating magnetic field, MIT graduate student Michael G. Christiansen and colleagues show in a recent Applied Physics Letters paper.

From Massachusetts Institute of Technology 19 Sep 2014

Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

Bioluminescence, nanoparticles, gene manipulation – these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors.

18 Sep 2014

3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity.

17 Sep 2014

Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy women in the third trimester of pregnancy.

From Novavax Inc. 17 Sep 2014

Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced a partnership with CytImmune to manufacture CYT-6091 for injection in preparation for Phase II clinical trials.

17 Sep 2014

CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease.

17 Sep 2014

Encouraging Preclinical Results from Study of Celator’s CPX-351 for Acute Lymphoblastic Leukemia

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of lead compound CPX-351 in hematological malignancies and support its ongoing clinical testing in pediatric patients with ALL. CPX-351 is currently being studied in a pivotal Phase 3 clinical trial in older patients with high risk (secondary) AML.

16 Sep 2014

Immunotope Granted World-Wide License of CaPtivate's CaP Nanoparticle Technology

CaPtivate Pharmaceuticals LLC, a Pennsylvania-based biotechnology company developing calcium phosphate (CaP)-based nanoparticle drug and vaccine delivery technologies, announced today that the company has entered a License Agreement with Immunotope Inc., another Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of viral infections and cancer.

16 Sep 2014

Nanomedicine News

New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

NANOBIOTIX Opens First US Office in Boston, Massachusetts

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

Encouraging Preclinical Results from Study of Celator’s CPX-351 for Acute Lymphoblastic Leukemia

Immunotope Granted World-Wide License of CaPtivate's CaP Nanoparticle Technology

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting